I added a little bit to my DNA position yesterday.
I think in the next two weeks, the following positive catalysts could push the price up around 10% (JMHO)
Lucentis approval with a clean and wide label (1+ billion opp) Avastin approval in 2nd line mCRC (250 million opp) Herceptin approval in adjuvant BC (1+ billion opp)